MONOGRAFÍA CANNABIs - Asociación Española de Patología Dual

Leighty E.G., Fentiman A.F., Foltz R.L. (1976). Longretainedmetabolites of δ 9 - y δ 8 -tetrahydrocannabinolidentified as novel fatty acid conjugates.Res. Commun. Chem. Pathol. Pharmacol.14:13-28.Lemberger L., Tamarkin N.R., Axelrod J., Kopin I.J.(1971). δ 9 -tetrahydrocannabinol: Metabolismand disposition in long-term marihuana smokers.Science 173:72-4.Magour S., Coper H., Fahndrich C., Hill R. (1976)Relationship between the subcellular distributionof ∆ 9 -tetrahydrocannabinol and its metabolitesin rat brain and the duration of the effecton motor activity. Life Sci. 18:575-84.Matsunaga T., Iwawaki Y., Watanabe K., YamamotoI., Kageyama T., Yoshimura, T. (1995) Metabolismof δ 9 -tetrahydrocannabinol by cytochromeP-450 isozymes purified from hepatic microsomesof monkeys. Life Sci. 56:2089-95.Malinovskij S.M. (1927) Stimulation of hemp seed(Cannabis Sativa L.). Mem. Inst. Agron.a´Lenin, 4:289-348.McIsaac W.M., Fritchie G.W., Idanpaam-HeikkilaJ.E., Ho B.T., Englert L.F. (1971). Distribution ofmarihuana in monkey brain and concomitantbehavioral effects. Nature 230:593-594.Mechoulam R., Devane W.A., Glaser R. (1992) Cannabinoidgeometry and biological activity. EnMarihuana/Cannabinoids: Neurobiology andNeurophysiology, Bartke A., Murphy L.L., eds.,Biochemistry and physiology os substanceabuse, vol IV, CRC Press, Boca Ratón, FL, pgs.1-34.Mendelson J.H. (1987) Marihuana. En Psychopharmacology:The Third Generation of ProgressMeltzer H.Y., ed., Raven Press, New York, pgs.1565-1571.Munro S., Thomas K.L., Abu-Shaar M. (1993) Molecularcharacterization of a peripheral receptorfor cannabinoids. Nature 365:61-65.Murphy L.L., Steger R.W., Smith M.S., Bartke A.(1990) Effects of ∆ 9 -tetrahydrocannabinol, cannabinoland cannabidiol, alone and in combinationson luteinizing hormone and prolactin release andon hypothalamic neurotransmitters in the malerat. Neuroendocrinology. 52:316-321.Ohlsson A., Lindgren J.E., Wahlen A., Agurell S.,Hollister L.E., Gillespie H.K. (1980a) Plasma ∆ 9 -tetrahydrocannabinol concentrations and clinicaleffects after oral and intravenous administrationand smoking. Clin. Pharmacol. Ther.28:409-16.Ohlsson A., Widman M., Carlsson Ryman T., StridC. (1980b) Plasma and brain levels of δ 6 -THCand seven monooxygenated metabolites correlatedto the cataleptic effect in the muse. ActaPharmacol. Toxicol. 47:308-17.Onaivi E.S., Green M.R., Martin B.R. (1990) Pharmacologicalcharacterization of cannabinoids inthe elevated plus maze. J. Pharmacol. Exp.Ther. 253:1002-1009.Paris M., Nahas G.G. (1984) Botany: the unstabilizedspecies. En Marihuana in science andmedicine. Nahas G.G., ed., Raven Press, NewYork, pgs. 3-36.Pérez-Reyes M., Timmons M.C., Lipton M., DavisK.H., Wall M.E. (1972) Intravenous injection inman of δ 9 -tetrahydrocannabinol and 11-hydroxyδ9 -tetrahydrocannabinol. Science 177:633-635.Pérez-Reyes M., Timmons M.C., Davis K.H., WallE.M. (1973) A comparison of the pharmacologicalactivity in man of intravenously administered∆ 9 -tetrahydrocannabinol, cannabinol andcannabidiol. Experientia 29:1368-1369.Pérez-Reyes M., Lipton M., Timmons M.C., WallM.E., Brine D.R., Davis K.H. (1973) Pharmacologyof orally administered ∆ 9 -tetrahydrocannabinol.Clin. Pharmacol. Ther. 14:48-55.Petitet F., Jeantaud B., Reibaud M., Imperato A.,Dubroeucq M.C. (1998) Complex pharmacologyof natural cannabinoids: evidence for partialagonist activity of ∆ 9 -tetrahydrocannabinoland antagonist activity of cannabidiol on ratbrain cannabinoid receptors. Life Sci 63:PL1-6.Rawich B., Roher G., Vardaris R.M. (1979) δ 9 -tetrahydrocannabinol uptake by adipose tissue;preferential accumulation in gonadal fat organs.Gen. Pharmacol 10:525-534.Razdan R.K. (1986) Structure-activity relationshipsin cannabinoids. Pharmacol. Rev. 38:75-149.Srivastava M.D., Srivastava B.I., Brouhard B. (1998)D9-tetrahydrocannabinol and cannabidiol altercytokine production by human immune cells.Immunopharmacology 40:179-185.Thomas B.F., Gilliam A.F., Burch D.F., Roche M.J.,Seltzman H.H. (1998) Comparative receptor bindinganalyses of cannabinoid agonists and antagonists.J. Pharmacol. Exp. Ther. 285:285-292.Turner C.E., Elsohly M.A., Boeren E.G. (1980) Constituentof Cannabis Sativa L. A review of thenatural constituent J. Nat. Prod. 43:169-234.Ramos, J.A.; Fernández, J. 57